Participants
PCP
Participants were healthy individuals 18 to 55 years of age, inclusive, who were experienced with nontherapeutic (recreational) drug use. In the Oxycodone Study (Study 1), participants had prior experience with recreational opioid use (defined as ≥10 lifetime occasions of use and ≥1 use in the 12 weeks prior to Screening). In the Ketamine Study (Study 2), participants had prior experience with NMDAR antagonists (e.g., ketamine, esketamine, phencyclidine [PCP], DXM), and had specifically used ketamine ≥1 in their lifetime and had ≥1 use of drugs for nonmedical purposes by either the intranasal or IV route in the past year. Participants were recruited separately for each study and were compensated according to IRB-approved parameters. In addition, participants had a body mass index (BMI) ranging from 18 to 35 kg/m